Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin detemir timed to individual need versus bedtime insulin glargine in type 2 diabetes with asymmetric day-night insulin requirements
NL-OMON25809Suspended
- Sponsor
- Amsterdam UMC
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Bedtime insulin glargine with Individually timed once-daily insulin detemir (2 arms). Primary endpoint: Composite glycaemic target without hypoglycaemia. Started Apr 2006; status: suspended.
02
Drugs
insulin detemirinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON25809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25809.